Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HLA class I expression in bladder carcinomas.

T Cabrera1, G Pedrajas, J M Cozar

  • 1Department of Clinical Analysis, Virgen de las Nieves University Hospital, University of Granada, Granada, Spain.

Tissue Antigens
|September 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.

United European gastroenterology journal·2026
Same author

Prognostic impact of clinical factors in MSI-H/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world study.

ESMO real world data and digital oncology·2026
Same author

Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer.

Advanced drug delivery reviews·2026
Same author

Low-frequency genetic variants in GAK enhance Golgi function and protect against Parkinson's disease.

medRxiv : the preprint server for health sciences·2025
Same author

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.

Redox biology·2024
Same author

Social environment as a modulator of immunosenescence.

Expert reviews in molecular medicine·2022
Same journal

Corrigendum.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update September 2015.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update August 2015.

Tissue antigens·2015
Same journal

Nomenclature for factors of the HLA system, update July 2015.

Tissue antigens·2015
Same journal

Four amino acid exchanges located in the alpha-2 domain specify the novel HLA-B*50:20 allele.

Tissue antigens·2015
Same journal

A novel HLA-A*02 variant, HLA-A*02:575, detected in a Taiwanese bone marrow hematopoietic stem cell donor.

Tissue antigens·2015
See all related articles

Human leukocyte antigen (HLA) class I loss is common in bladder carcinomas, affecting 72% of tumors studied. This alteration is linked to tumor differentiation and recurrence, suggesting immune evasion mechanisms in bladder cancer.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Human leukocyte antigen (HLA) class I molecules are crucial for immune surveillance.
  • Loss of HLA class I expression is observed in various carcinomas, potentially aiding tumor immune evasion.
  • The frequency and specific patterns of HLA class I alterations in bladder cancer require further investigation.

Purpose of the Study:

  • To investigate the prevalence and types of HLA class I expression alterations in bladder carcinomas.
  • To correlate these HLA class I alterations with histopathological features and clinical outcomes.

Main Methods:

  • Analysis of HLA class I expression in 72 bladder carcinoma samples.
  • Classification of altered HLA class I phenotypes (total loss, locus-specific loss, allelic loss).

Related Experiment Videos

  • Statistical comparison with histopathological parameters like differentiation and recurrence.

    • Main Results:

    • 72% of bladder carcinomas exhibited alterations in HLA class I expression.
    • Specific phenotypes included total loss (25%), locus-specific loss (12%), and allelic loss (35%).
    • Significant associations were found between HLA class I alterations, tumor differentiation, and recurrence.

    Conclusions:

    • Alterations in HLA class I expression are frequent in bladder carcinomas.
    • These alterations may play a role in the immune escape of bladder tumors.
    • HLA class I expression status is a potential prognostic marker for bladder cancer differentiation and recurrence.